Gone gone gone

Quote


















HEY JACKIE, HAVE YOU NOTICED PEOPLE ARE JUMPING SHIP OR ARE YOU THAT IGNORANT THAT YOU DON'T REALLY CARE? AS A LEADER, YOU SHOULD BE SITTING BACK AND PONDERING WHAT YOU ARE DOING WRONG. YOU ARE THE WORST LEADER I HAVE EVER KNOWN IN MY CAREER. I SEE YOU ALMOST EVERY DAY AND I STILL SHAKE MY HEAD IN DISBELIEF THAT YOU HAVE THE ROLE YOU DO. JAPAN IS ON TO YOU AND COMING AFTER YOU WITH EVERYTHING THEY HAVE. THEY HAVE SEEN THE NUMBERS DROP IN SALES PEOPLE AND ARE QUESTIONING MJ ON WHAT THE HELL IS GOING ON. SO, HOPE YOU SAVED SOME VACATION DAYS TO MAKE UP FOR SOME OF YOUR SALARY YOU ARE ABOUT TO LOSE.
OH, BY THE WAY, LIKE YOU ALWAYS SAY, "IT'S NOT PERSONAL"
 






If you are in home office then you would know that JB has no authority when it comes to money. MJ has COMPLETE control. People are leaving because they can make substantially more money doing the same job. Those left are either fine with what they are making or haven't had the right offer. Turnover is costly. Can't believe someone hasn't put together an economic model showing MJ the price of constant turnover vs the much smaller cost of paying industry standard for this type of position.

When Injectafer was launched, AR had a solid team of tenured leaders and mentors to help the new reps get started. MJ has no idea what a difference that made. Not anymore. Qualified people will take the job and keep looking for something better. Under qualified ones will get the experience that enables them to get more $ somewhere else on ARs time.

It's time to neutralize the poison attitudes in home office that hate the sales force and have absolutely no clue what we do every day. Look for 2-3 more to leave next month. 3-4 in March, 3-5 in April.....etc.
 






I love how we get an email asking to tell how we can change things to make people stay. Here's a hint: quit promoting each other in the home office all the time. New titles and raises while the sales force is underpaid. If you want to keep the sales force throw some titles and raises our way.
Oh, and no roommates at meetings. That sucks.
 






Oh come on! We all know that Injectafer sells itself. Any pc rep making 45k a year can do it. Leadership at AR is so much smarter than the same at the biotechs aND start ups that are actively recruiting AR losers. People with no sales experience, multiple responsibilities they are severely under qualified for, well known resentment and disdain for the sales force, been caught in several gross misrepresentations, topping it off with a shitty attitude, make great directors. Don't forget the consultant that has given so much helpful advice and has greatly impressed our customers.
 
























Saw an ad and was thinking of applying....but sounds like a horror. Is this for real? Low, low, low ball income and waiting 2 months for healthcare? Thats third rate...worse than even a temp gig.


..maybe I better pass.

Will not get involved with a D- company. Shame on this company if the information here is true....you get what you pay for!
 






May be a new IV iron on the Horizon. Helsinn agreed to market it in the US. Seems very similar to Inj without the hypophosphotemia, not that anyone cares about that. Looks like an excellent safety profile at even higher doses. Interesting. Another Keryx like raid of AR talent?
 






Helsinn and Pharmacosmos Enter into an Exclusive License Agreement for the Development and Commercialization of Monofer® in US
Print
Lugano, Switzerland and Holbæk, Denmark, January 8, 2015 – Helsinn Group and Pharmacosmos A/S today jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer®, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia.

Agreement highlights:
Helsinn has obtained the exclusive rights to commercialize Monofer® and any other iron isomaltoside 1000 products developed by Pharmacosmos in the US.

Pharmacosmos is eligible for milestone payments of up to USD 130 million for MonoferÒ in iron deficiency anemia in the US. In addition, Pharmacosmos will be eligible to receive further payments for the manufacture and supply of MonoferÒ to Helsinn in the US.

Helsinn’s Chief Executive Officer, Riccardo Braglia, commented: “Helsinn is committed to improving the lives of patients by offering medicines which enable them to get the most out of every day, optimizing their quality of life and promoting their ability to remain on treatment regimens. Monofer® provides a high dose iron replacement in a single administration, which may offer anemic patients a new, more convenient treatment option for rapidly restoring their iron stores and thereby, improve their symptom burden. We look forward to collaborating with Pharmacosmos and bringing MonoferÒ to the US market.”

Pharmacosmos’ Chief Executive Officer, Lars Christensen, commented: “This is a very important milestone for Pharmacosmos. The US market is the biggest market in the world. We believe that Monofer® will serve yet unmet clinical needs with a clear potential to improve outcomes and convenience for patients suffering from Iron Deficiency Anemia in the US. Helsinn's strong foothold in the hematology and oncology combined with Pharmacosmos’ expertise on iron deficiency anemia will provide an excellent platform for the introduction of Monofer® in the US. I expect that our alliance with Helsinn will bring further growth, significantly strengthening our ambition and possibilities to establish MonoferÒ as the leading brand for iron deficiency anaemia management.”

About Monofer®
Monofer® (10% iron isomaltoside 1000) is an iron-carbohydrate complex for intravenous administration. Monofer® is already marketed in more than 30 countries, primarily in Europe, for the treatment of iron deficiency anemia. Monofer® is under development in the rest of the world, including North America and Japan. It is believed that the structure of MonoferÒ differentiates it from other intravenous iron replacement therapies, allowing the possibility to administer high iron doses in one visit over a short period of time for the benefit and convenience of patients and healthcare professionals. Monofer® is manufactured by Pharmacosmos, Denmark.

About iron deficiency anemia (IDA)
Iron deficiency anemia (IDA) is a debilitating condition which affects almost 2 billion people worldwide, including over 7 million people in US. IDA is often associated with many chronic diseases such as renal diseases (including Chronic Kidney Disease), cancers (including chemotherapy induced anemia), gynecologic disorders (including abnormal uterine bleeding) and inflammatory bowel disease (IBD).

The US market is estimated to be worth more than USD 600 million in 2014 and is expected to exceed USD 1 billion early after 2020.

About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in‐licenses early‐to‐late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out‐licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.

About Pharmacosmos A/S
Pharmacosmos A/S is a family-owned Danish pharmaceutical company with headquarters in Holbæk, Denmark. It was founded in 1965 and today sells its products in the UK and Scandinavia through its own subsidiaries and across the World through partners. Pharmacosmos is a global leader in the development and marketing of medicines for the treatment of iron deficiency anemia. Pharmacosmos’ ongoing commitment to R&D leverages its unique carbohydrate production platform along with unrivaled expertise in the synthesis of iron-carbohydrate complexes to bring better treatments for patients suffering from iron deficiency. Its state-of-the-art facilities in Denmark are approved by both the Danish Medicines Agency and the US Food & Drug Administration.

For more information, please contact:
Helsinn Group Pharmacosmos A/S
Paola Bonvicini Tobias S. Christensen
Head of Communication & Press Office Vice President, Corporate
Tel: +41 91-985-21-21 Development & Strategy
info-hhc@helsinn.com Tel: +45 40 20 16 62
Switchboard: +45 59 48 59 59
tsc@pharmacosmos.com

For media/external inquiries

Helsinn Group
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Laura Thornton
Tel: +44 (0)203 709 5700
Helsinn@consilium-comms.com

Pharmacosmos A/S
Fonnesbech & Estrup
Adam Estrup
Tel: +45 28 74 87 10
adam@estrup.dk
Helsinn and Pharmacosmos Enter into an Exclusive License Agreement for the Development and Commercialization of Monofer® in US
 






We emit have to worry about this for a while. Look how long it took Injectafer to get to market in the US. The much bigger concern should be the revolving door for the TMs. Great place to rest while you find a job that pays more.

Jackie gets it. Making some positive moves, except for letting Liane take on New position. Temporary or not, huge mistake. She's been blamed for things that were not her doing. Framed for things she did not say. Damage coming from 1 , maybe 2 people
 












Really? Scott H. left? We've been trying to recruit him for years. One of the best coaches in the industry. Has to be a big loss for your company. Do you have his personal contact information.
 






Would love to see the business plan for the next fiscal year. Wonder if a 50% turnover every 6 months is calculated into expensives? Then again, we could just hire more telemarketers to pick up the slack while we train some severely under experienced peopled or their next job somewhere else.

No offense to new hires. Heard some are great (pit stop until the next offer comes through) and some are clueless(stick around long enough to get the buy bill oncology hospital experience and then go on to make a lot more money somewhere else within a year.) it's all good.
 












Now for the 3rd (4th maybe)wave of people leaving. Remember when this used to be the place where no one left and everyone wanted to be? What if what if what if you had paid the industry standard from the original launch (or at least had a good incentive plan paying people for growth) released the misleading (being extremely kind here) bogus consultant 1 year earlier, and simply developed an advisory board to investigate half baked expensive ideas (hub, telemarketers, play book, etc) before launching out to the whole field??? How much money and time would have been saved? Where would your sales be now? My gosh Mary J! With a little for sight u would actually have even more money to spend now then you did before! You lost so many great people and a lot of business in the lag between hirings. Ready to hire and train a whole new NE Team...again? How about FL and CA?
 






Wow, so let me get this straight- you mean to say that FCM could have been a home run from the get-go except the TMs decided to do some work "slow down", some kind of passive - agressive underperformance because pay was not at the top of pharma scale? So the entire field just held back?
 






Top Bottom
Back
Quote